文献速递妇科

超声引导微波消融治疗症状性子宫肌瘤的系统评价与Meta分析

Ultrasound-guided Microwave Ablation in the Management of Symptomatic Uterine Myomas: A Systematic Review and Meta-analysis.
PubMed 文献 · J Minim Invasive Gynecol · 2021-06-28

该系统评价与Meta分析纳入2000年1月至2021年1月间10项研究共671例症状性子宫肌瘤患者,评估超声引导微波消融的临床效果与安全性。结果显示UFS评分显著下降、QoL评分显著升高、血红蛋白显著升高,肌瘤体积缩小率达85.3%,无严重不良事件,轻微不良事件发生率21.1%。

要点

  • 超声引导微波消融可显著改善症状性子宫肌瘤患者的症状评分与生活质量。
  • 随访时血红蛋白显著升高,肌瘤体积缩小率达85.3%。
  • 无严重不良事件报告,轻微不良事件发生率为21.1%。

核心结论

  • 超声引导微波消融是治疗症状性子宫肌瘤有效且安全的微创疗法。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Web of Science核心合集、Cochrane Library、Embase、Scopus和Google Scholar从2000年1月至2021年1月的研究。
  • 共纳入10项研究、671例症状性子宫肌瘤患者,采用纽卡斯尔-渥太华量表评估偏倚风险与证据质量。

主要发现

  • 与基线相比,UFS评分显著下降(SMD 3.37;95%CI 2.27-4.47;p<.001;下降率65.9%)。
  • QoL评分显著升高(SMD -3.12;95%CI -3.93至-2.30;p<.001;升高率72.0%)。
  • 血红蛋白浓度显著升高(SMD -2.13;95%CI -3.44至-0.81;p=.002;升高率30.3%)。
  • 平均手术时间34.48分钟(95%CI 22.82-46.13;p<.001),肌瘤体积缩小率85.3%(95%CI 82.7%-88.0%;p<.001)。
  • 无严重不良事件报告,轻微不良事件发生率21.1%(95%CI 15.1%-27.0%;p<.001)。

临床怎么用

  • 对于症状性子宫肌瘤患者,超声引导微波消融可作为微创治疗选择,能改善症状、生活质量及血红蛋白水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This systematic review and meta-analysis aimed to evaluate the clinical effects and safety of ultrasound-guided microwave ablation (MWA) for the treatment of symptomatic uterine myomas. DATA SOURCES: We searched PubMed, Web of Science Core Collection, Cochrane Library, Embase, Scopus, and Google Scholar for studies from January 2000 to January 2021. METHODS OF STUDY SELECTION: We included all studies that reported the clinical outcomes of ultrasound-guided MWA in women with symptomatic uterine myomas. Two researchers conducted the study selection according to the screening criteria. TABULATION, INTEGRATION, AND RESULTS: We evaluated the risk of bias and evidence quality using the Newcastle-Ottawa scale. Two researchers independently extracted information from the included studies. We extracted the standardized mean difference (SMD) and pooled proportion with a 95% confidence interval (CI) for the outcome measures of interest. A total of 10 studies representing 671 patients were included. The Uterine Fibroid Symptom and Quality of Life (UFS-QoL) questionnaire was used to assess the clinical effects. Compared with baseline, the UFS scores decreased significantly (SMD 3.37; 95% CI, 2.27-4.47; p <.001; reduction rate 65.9%), QoL scores increased significantly (SMD -3.12; 95% CI, -3.93 to -2.30; p <.001; rate of increase 72.0%), and hemoglobin concentration increased significantly (SMD -2.13; 95% CI, -3.44 to -0.81; p = .002; rate of increase 30.3%) at follow-up. The mean operation time was 34.48 minutes (95% CI, 22.82-46.13; p <.001). The rate of reduction in myoma volume after MWA was 85.3% (95% CI, 82.7%-88.0%, p <.001). No major adverse event was reported, and the incidence of minor adverse events was 21.1% (95% CI, 15.1%-27.0%, p <.001). CONCLUSION: Ultrasound-guided MWA is an effective and safe minimally invasive therapy for symptomatic uterine myomas.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Liu L, Wang T, Lei B, et al. Ultrasound-guided Microwave Ablation in the Management of Symptomatic Uterine Myomas: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol. 2021. PMID: 34197954. doi:10.1016/j.jmig.2021.06.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。